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Of the 56 therapeutic monoclonal antibody products currently marketed in the US, four now target infectious 
disease indications. An additional 40 recombinant antibodies are in clinical trials for infectious indications, with 
29 in phase II or III trials.  The evolution of antibiotic-resistant bacteria, the emergence of new pathogens, and a 
growing population of immunocompromised individuals means that in many cases antibodies are an 
increasingly attractive therapeutic option.  Next-generation antibody formats, including antibody-drug conjugates 
and single-domain antibodies as well as antibody mixtures and bispecific antibodies provide access to novel 
therapeutic mechanisms and allow for targeting a wider range of epitopes. This talk will provide an overview of 
recent advances in the field and highlight two on-going projects in my lab. First, to address a resurgence in 
pertussis in high resource countries and continued high rates of morbidity and mortality in low resource 
countries, we have developed and antibody therapeutic neutralizing the toxin primarily responsible for 
symptoms. This antibody has been engineered for high affinity binding, reduced immunogenicity and extended 
serum half-life. We have also characterized its mechanism of action, using biochemical, structural and cellular 
assays. We have shown hu1B7 is protective against disease in mouse and adolescent baboon models of 
disease.  Moreover, a single dose can prevent disease symptoms in a neonatal baboon model when 
administered five weeks before experimental challenge. Second, to address issues with recurrent 
cytomegalovirus infection in immuno-suppressed individuals, we envision a bispecific antibody able to redirect 
any passing T cells toward CMV suppression. In our first iteration of this therapeutic, we aim to target infected 
cells via a T cell receptor (TCR) binding the immuno-dominant peptide-HLA complex. Since TCRs are typically 
low affinity and express poorly as soluble molecules, we have used a novel eukaryotic-based cell display 
system that allowed us to rapidly identify variants with higher affinity and enhanced stability. We have generated 
TCR variants with up to 100-fold improved affinity that retain exquisite peptide selectivity. We will report our 
initial efforts to use this modified TCR to target CMV-infected cells.  
 
 
